

# Tamara P Miller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9216570/publications.pdf>

Version: 2024-02-01

39  
papers

366  
citations

840776

11  
h-index

839539

18  
g-index

40  
all docs

40  
docs citations

40  
times ranked

561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	1.6	47
2	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	1.5	40
3	Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 0001. <i>Pediatric Blood and Cancer</i> , 2011, 57, 492-498.	1.5	38
4	Using electronic medical record data to report laboratory adverse events. <i>British Journal of Haematology</i> , 2017, 177, 283-286.	2.5	31
5	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 141-148.	4.1	29
6	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	1.5	21
7	Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. <i>Cancer</i> , 2017, 123, 3781-3790.	4.1	18
8	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. <i>Cancer Medicine</i> , 2015, 4, 1356-1364.	2.8	17
9	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. <i>PLoS ONE</i> , 2018, 13, e0192529.	2.5	16
10	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
11	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
12	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, e312-e320.	0.5	10
13	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. <i>Cancer</i> , 2016, 122, 3394-3400.	4.1	8
14	Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28570.	1.5	8
15	Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report. <i>Journal of Patient Safety</i> , 2022, 18, e672-e679.	1.7	7
16	Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 899-908.	1.3	6
17	A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. <i>Haematologica</i> , 2022, 107, 1185-1188.	3.5	6
18	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Complications preceding early deaths in Black and White children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26712.	1.5	4
20	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
21	Feasibility and acceptability of an animatronic duck intervention for promoting adaptation to the inpatient setting among pediatric patients receiving treatment for cancer. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27984.	1.5	4
22	Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 280-286.	2.5	4
23	Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 126-131.	2.3	3
24	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN). <i>Blood</i> , 2019, 134, 333-333.	1.4	3
25	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 369-369.	1.4	3
26	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021, 138, 3398-3398.	1.4	3
27	Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium. <i>Blood</i> , 2019, 134, 1304-1304.	1.4	2
28	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28315.	1.5	1
29	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28940.	1.5	1
30	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group. <i>Blood</i> , 2013, 122, 931-931.	1.4	1
31	Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL). <i>Blood</i> , 2019, 134, 5809-5809.	1.4	1
32	Pediatric EBV-negative monomorphic post-solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10012-10012.	1.6	1
33	Reply to H.S.L. Jim et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1135-1135.	1.6	0
34	Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3697-3697.	1.4	0
35	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 2286-2286.	1.4	0
36	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. <i>Blood</i> , 2015, 126, 530-530.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium. <i>Blood</i> , 2019, 134, 3814-3814.	1.4	0
38	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1970-1970.	1.4	0
39	Outcome of Post Solid Organ Transplant Burkitt Lymphoma (PSOT-BL): A Report from the Pediatric PTLD Collaborative (PPC). <i>Blood</i> , 2021, 138, 2498-2498.	1.4	0